Roche's Ventana MMR RxDx Panel Test Receives the US FDA's Approval as First CDx to Detect dMMR Solid Tumor
Shots:
- The FDA has approved the Ventana MMR RxDx Panel test as a CDx to identify patients with dMMR advanced solid tumors- who may be eligible for Jemperli monothx.- based on the results of the MMR biomarker test
- Ventana MMR RxDx Panel provides access to clinicians with fully automated panel of MMR biomarkers tested by IHC
- The test assesses the expression of MMR proteins in FFPE tumor tissues. The test and Jemperli were earlier received approval for use in endometrial cancer in Apr’2021
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com